Ealixir FCF Conversion
FCF Conversion Rate (FCF/EBITDA) of Ealixir (EAXR) as of Jul 12, 2026.
Get this data via API
Financial Data API
FCF Conversion
0.00
Last updated:
FCF Conversion Rate (FCF/EBITDA) of Ealixir is 2026 0.00 . FCF Conversion Rate (FCF/EBITDA) of Ealixir was 2025 34.07 % . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Ealixir Stock analysis
What does Ealixir do? Ealixir Inc is a biotechnology company founded in 2012 by Dr. Nithin Rajan. Dr. Rajan earned his doctoral degree in biomedical science from the University of Ottawa and has over ten years of experience in the field of biomedical research.
Ealixir Inc is an innovative firm specializing in the development of novel therapeutic technologies based on cell and proteomic research. Ealixir's goal is to help patients with serious or chronic illnesses by offering biological solutions that support the body's natural functions.
Ealixir has developed the concept of "lifestyle medicine," aiming to develop treatments that not only combat diseases but also influence the patient's lifestyle to help them lead a healthier life. The company follows an integrative approach, combining the use of medications and other therapeutic approaches.
Ealixir specializes in ingredients and technologies that have the potential to stimulate and activate the body to promote natural regenerative processes. One of Ealixir's significant products is the Arthritin system, which is used for the treatment of arthritis and pain.
Arthritin utilizes a blend of pain relief, inflammation inhibitors, and regeneration promoters to effectively alleviate arthritis pain and reverse the damage caused by the disease to the joints.
Ealixir is also a pioneer in the development of nano "in-minutes" technologies, where nanoparticles are used to actively transport active substances to specific target cells, thereby achieving results in minutes rather than hours.
Another important product of Ealixir is Collagenix, a beauty product that uses a blend of collagen, vitamins, and minerals to improve skin structure and wrinkle depth.
Ealixir also offers products for animal care and medicine. The company has developed a new product for wound care in pets using the Ealixir technology. The solution consists of antibacterial ingredients and promotes the growth of new tissue.
Ealixir also focuses on researching dietary supplements that contribute to overall health and well-being. The company pays special attention to proteins, magnesium, and omega-3 fatty acids. The range includes CBD oil and support for restful sleep.
Overall, Ealixir has established itself as a leading company in biomedical research and the development of innovative therapies. The company's products are at the forefront of technology and are developed and tested by a great team of researchers and scientists. The brand has experienced rapid growth in recent years and will undoubtedly achieve many successes in the future, benefiting both patients and animal lovers as well as people who value health and wellness. Ealixir is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Ealixir stock
On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Ealixir since 2006 – with annual values, charts, and detailed analysis.
Access this data via the Eulerpool API
Cash Flow — Ealixir
Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A
All Key Metrics — Ealixir
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth